Teceleukin

Summary

Teceleukin is a recombinant human interleukin-2 (rIL-2) produced in E. coli, differing from aldesleukin in that it retains the native methionine at the N-terminus and has no cysteine substitution. It was investigated primarily for antitumor and antiviral (HIV) immunotherapy. Clinical development was largely discontinued due to toxicity and limited efficacy advantages over existing agents.

Mechanism of Action

Binds to IL-2 receptors (IL-2Rα/β/γ) on T cells, NK cells, and other lymphocytes, stimulating proliferation, differentiation, and cytotoxic activity; enhances immune surveillance and antitumor immunity.

Routes of Administration

Goals & Uses

• NK cell and T cell expansionImmunologyModerate
• HIV/AIDS immune reconstitutionInfectious Disease / ImmunologyLow
• Antitumor immunotherapyOncologyLow

Contraindications

• Autoimmune disease (active)ImmunologicalHigh
• Organ transplant recipients on immunosuppressionTransplantHigh
• Severe cardiac dysfunctionCardiovascularHigh

Adverse Effects

• Capillary leak syndromeVascularCommonLeakage of fluid from blood vessels into tissues
• ThrombocytopeniaHematologicUncommonLow platelet count
• HypotensionCardiovascularCommonLow blood pressure
• Neurotoxicity / mental status changesNeurologicalUncommon
• Fever and chillsConstitutionalCommon
• Nausea and vomitingGastrointestinalCommon

Drug Interactions

• Antihypertensive agentsModerate
• Nephrotoxic agentsModerate
• CorticosteroidsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative
• Patients with renal or hepatic impairmentOrgan FunctionRelative

Regulatory Status

• European UnionUnapprovedNo EMA approval; early clinical research only.
• United StatesInvestigationalInvestigated in Phase I/II trials; never received FDA approval.
• United KingdomUnapprovedNo regulatory approval in the UK.

Never received FDA or EMA approval. Investigated in Phase I/II clinical trials in the late 1980s and 1990s for cancer and HIV. Not currently in active clinical development.

Evidence & Sources

No sources recorded yet.